Skip to content
Back to meeting Original
SEOM· @_SEOM · X·· 7 hours agoScore70

KRASCENDO

Body · original

🔬 #ESMO26 | El Dr. @javierDcastro , presidente de @_SEOM, analiza KRASCENDO 1 (LBA5), presentado en la Sesión Presidencial del Congreso @myESMO 2026.

🧬 Divarasib reduce un 42% el riesgo de progresión o muerte y un 44% el de muerte frente a sotorasib/adagrasib en CPNM con KRAS G12C.

31 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

Source: SEOM · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.